Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Domestic, Prospective, Non-interventional Study of Remazolam Methyl Benzene Sulfonic Acid for Injection in Real-world Clinical Practice

NCT05254366 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.

NCT NCT05254366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05254366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Domestic, Prospective, Non-interventional Study of Remazolam Methyl Benzene Sulfonic Acid for Injection in Real-world Clinical Practice
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
January 30, 2022
Completion date
February 8, 2023
Enrollment
2,022 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

gastroscopic and colonoscopic sedation